ReviewInternational journal of nanomedicine2025
Hepatotoxicity of Nanoparticle-Based Anti-Cancer Drugs: Insights into Toxicity and Mitigation Strategies.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Advances in miR‑200c regulation of apoptosis, pyroptosis and autophagy in disease (Review).Molecular medicine reports · 2026Review
- Biomaterial-based strategies for postoperative residual tumors: From margin clearance to immune control and tissue repair.Materials today. Bio · 2026Review
- Review
- Overcoming Tumor Hypoxia in Photodynamic Therapy: A Comprehensive Review of Oxygen-Delivery Carriers and Type I Photosensitizers.International journal of molecular sciences · 2026Review
- Nanotechnology in Cancer Therapy: How Nanoparticles Are Shaping the Future of Personalized Treatment.ACS nano medicine · 2026Review
- Nanocarrier-mediated targeting of NF-κB and JAK/STAT signaling pathways in hepatocellular carcinoma: mechanisms and therapeutic strategies.Journal of experimental & clinical cancer research : CR · 2026Review
- Broccoli-mediated gold nanoparticles: Eco-friendly synthesis and nano-bio interactions promoting wound healing and targeted cytotoxicity.Journal, genetic engineering & biotechnology · 2026Article
- Lipid-Based Nanocarriers for Curcumin Delivery: A Promising Strategy in The Management of Inflammatory Diseases.International journal of nanomedicine · 2026Review
- Nanosystem-Mediated Phototherapy (PDT/PTT) - Chemodynamic Therapy for Synergistic Antitumor Therapy: Strategies and Advances.International journal of nanomedicine · 2026Review
- The Dual-Faceted Role of Metal-Based Nanomaterials in Hepatic Fibrosis Therapy.International journal of nanomedicine · 2026Review
- Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy.International journal of nanomedicine · 2026Review
- Selegiline, a monoamine oxidase-B inhibitor as a modulator of metabolic reprogramming for cancer therapy: a review.Frontiers in pharmacology · 2026Review
- Coconut oil/lauric acid-based nanodrug formulation: a multifunctional platform for enhancing cancer therapy and mitigating toxicity.Frontiers in cell and developmental biology · 2026Review
- Smart nanoplatforms for early detection and immune modulation in lung cancer.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant progress in developing novel, efficient nanoparticle-based anticancer drugs, hepatotoxicity remains a major challenge. The liver, as the primary organ responsible for detoxification, is particularly susceptible to nanoparticle accumulation, particularly through the action of Browicz-Kupffer cells (B-KCs) and liver sinusoidal endothelial cells (LSECs). These phagocytic cells accumulate nanoparticles, leading to the production of reactive oxygen species (ROS), interleukin 1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), which ultimately cause hepatocyte damage. In recent years, various nanoparticle modification strategies have been investigated to reduce hepatotoxicity. One of the most common and effective approaches is the PEGylation of liposomes and graphene nanoparticles, which decreases their uptake by the liver via the reticuloendothelial system (RES). Other strategies to mitigate hepatotoxicity are also being explored, including the incorporation of negatively charged lipids into liposomes, charge manipulation of inorganic-organic nanoparticles, the use of specific protein-based nanoparticles that selectively bind to cancer cells (thereby reducing hepatic uptake), the use of appropriate viral capsids in the production of virus-like protein-based drugs, and the manipulation of the size of protein, metal and graphene nanoparticles. Moreover, modifications aimed at pH-responsive drug release are employed in liposomes, self-assembled and graphene nanoparticles. This article discusses several types of nanoparticles used as carriers in currently approved therapies and explores potential strategies to minimize their hepatotoxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.